Testing an Intergenerational Model of Suicide Risk in Mother-child Dyads
Launched by UNIVERSITY OF PITTSBURGH · Jun 11, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a mother’s emotions and experiences with suicide risk can affect their children, specifically those aged 9 to 11. The researchers want to understand how these risks are passed from mothers to their children. If you decide to participate, you will be randomly assigned to one of two groups: one that receives special training called DBT Skills Training, which helps with managing emotions, or a group that receives standard care. Over the course of a year, you will take part in a baseline assessment and four follow-up assessments to track progress.
To be eligible, you must be a biological mother with legal custody of your child in the specified age range, and you should have a history of suicidal behavior. However, if you or your child have certain medical conditions that could affect your emotional health or if you’ve received DBT in the past six months, you may not qualify. This study is currently recruiting participants and aims to gather important information that could help improve emotional support for families facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Biological mothers with legal custody of target child between 9-11
- • Confirmed lifetime Biological mothers with legal custody of target child between 9-11
- • Confirmed lifetime history of suicidal behavior for mothers of suicidal behavior for mothers
- Exclusion Criteria:
- • Any mothers and children with major medical illnesses that might be associated with organic personality changes or ER difficulties (e.g. Parkinson's Disease, seizure disorders)
- • Cardiac nervous system abnormalities that would influence physiological readings
- • Previous DBT (Dialectical Behavior Therapy) in the last six months
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Stephanie D Step, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported